Analyst IMS Investment Management Services Ltd. Buys 2,756 Shares of Johnson & Johnson $JNJ

Analyst IMS Investment Management Services Ltd. lifted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 42.3% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 9,271 shares of the company’s stock after purchasing an additional 2,756 shares during the period. Analyst IMS Investment Management Services Ltd.’s holdings in Johnson & Johnson were worth $1,918,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Abich Financial Wealth Management LLC bought a new stake in shares of Johnson & Johnson during the 3rd quarter worth approximately $26,000. Evolution Wealth Management Inc. bought a new stake in shares of Johnson & Johnson during the 2nd quarter worth approximately $27,000. Clayton Financial Group LLC bought a new stake in shares of Johnson & Johnson during the 3rd quarter worth approximately $28,000. Semmax Financial Advisors Inc. raised its stake in shares of Johnson & Johnson by 55.0% during the 2nd quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock worth $31,000 after purchasing an additional 72 shares in the last quarter. Finally, Turning Point Benefit Group Inc. bought a new stake in shares of Johnson & Johnson during the 3rd quarter worth approximately $41,000. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Down 0.9%

JNJ opened at $240.87 on Tuesday. Johnson & Johnson has a 1-year low of $141.50 and a 1-year high of $251.71. The stock’s fifty day simple moving average is $240.25 and its 200 day simple moving average is $213.73. The company has a current ratio of 1.03, a quick ratio of 0.77 and a debt-to-equity ratio of 0.48. The stock has a market cap of $580.15 billion, a PE ratio of 21.80, a price-to-earnings-growth ratio of 2.41 and a beta of 0.34.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Saturday, January 31st. The company reported $2.46 earnings per share for the quarter. The firm had revenue of $24.28 billion for the quarter. Johnson & Johnson had a return on equity of 33.04% and a net margin of 28.46%. As a group, research analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on JNJ shares. Guggenheim increased their price target on Johnson & Johnson from $227.00 to $240.00 and gave the company a “buy” rating in a research note on Friday, January 23rd. Argus increased their price target on Johnson & Johnson from $210.00 to $240.00 in a research note on Friday, January 23rd. UBS Group restated a “buy” rating on shares of Johnson & Johnson in a research note on Monday, January 5th. Leerink Partners increased their price target on Johnson & Johnson from $201.00 to $232.00 and gave the company a “market perform” rating in a research note on Thursday, January 22nd. Finally, Bank of America restated a “neutral” rating on shares of Johnson & Johnson in a research note on Monday, March 2nd. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $236.91.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, EVP Vanessa Broadhurst sold 6,197 shares of the stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $243.39, for a total transaction of $1,508,287.83. Following the transaction, the executive vice president owned 23,003 shares in the company, valued at $5,598,700.17. This trade represents a 21.22% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Timothy Schmid sold 22,623 shares of the stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $244.33, for a total value of $5,527,477.59. Following the transaction, the executive vice president owned 26,769 shares in the company, valued at $6,540,469.77. The trade was a 45.80% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 30,142 shares of company stock worth $7,360,528 in the last quarter. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.